Skip to main content

Table 1 Patient data, including age, sex, type of tumor, location of metastases, and earlier treatments

From: Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy

Patient number

Age (years) at first treatment cycle

Sex

Tumor type

Metastases

Earlier treatments

1

61

M

Rectal carcinoid

Abd, local, Sk

Y, Mayo

2

56

M

MC

Abd

N

3

39

F

EPT

Li

Y

4

59

F

EPT

Li, Sk

Y

5, one kidney

36

M

ICT

Retroper

Y

6

65

M

LC

Pl, Br

Y

7

53

M

EPT

Li, Pa

Y

8, Li transpl

67

M

Gluc

Li, Sk

Y, Mayo

9, Li transpl

57

F

Ins

Abd

N

10, Li transpl

46

F

MC

Sk (arm)

N

11

54

M

EPT

Abd

Y, Mayo

12

49

F

MC

Abd, Sk

N

13

54

F

Duodenal carcinoma/gastrinoma

Abd, Li

N

14

72

M

MC

Li, Abd, Th

N

15, Li transpl

46

F

Gastrinoma

Li, Abd

Y, Mayo

16

55

M

EPT

Li

Y

17

66

M

MC

Li Sk

N

18

69

M

Carcinoid

Li, Abd, Th

N

19

68

F

Carcinoid

Li

N

20

41

M

Carcinoid/tailgut cyst

Li, Sk

N

21

77

F

MC

Abd, Th

N

22

61

M

MC

Li, Abd, Th

N

23

64

F

Rectal carcinoid

Li

Y (ovarian carcinoma > 20 years ago)

24

65

M

EPT

Li, Pa

N

25

57

M

MC

Abd, Li, Supraclav

N

26

63

M

Rectal carcinoid

Li, Sk

N

27

71

M

Rectal carcinoid

Abd, Li, Sk

N

28

78

F

Carcinoid, unknown primary

Li, Abd, Pelvis

N

29

56

M

MC

Li, Abd

N

30

65

M

MC

Retroper, Orb, Med

N

31

78

F

MC

Abd, Li

N

32

75

M

MC

Li, Sk

N

33

79

F

MC

Li, Sk

N

  1. MC, midgut carcinoid; EPT, endocrine pancreatic tumor; ICT, islet cell tumor; LC, lung carcinoid; Gluc, glucagonoma; Abd, abdomen; Sk, skeleton; Li, liver; Pl, pleura; Br, brain; Pa, pancreas; Th, thorax; Med, mediastinum; Retroper, retroperitoneum; Supraclav, supraclavicular lymph nodes; Orb, orbita; Ins, insulinoma; Mayo, chemotherapy according to the Mayo Clinic program; transpl, transplant; F, female; M, male.